SCHEMBL4115779

SCHEMBL4115779

NCCC[C@@H]1[C@@H](Nc2nccc(N3CCCCCC3)n2)CCN1C1CCN(C(=O)CC2CCCC2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ CXCR4 P61073 2/20 0.41
▸ FAAH O00519 1/20 0.38
▸ HRH4 Q9H3N8 8/20 0.36
▸ MRGPRX1 Q96LB2 1/20 0.35
▸ MAPK8 P45983 2/20 0.34
▸ POLB P06746 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ HRH3 Q9Y5N1 1/20 0.33
▸ CCR4 P51679 1/20 0.32
▸ SMO Q99835 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4114612 0.93 CXCR4 (0.43) ALDH1A1KDM4EHSD17B10CXCR4HRH4
SCHEMBL2011571 0.89 CXCR4 (0.42) CXCR4FAAHHRH4MAPK8CCR4
SCHEMBL2007163 0.89 CXCR4 (0.42) CXCR4FAAHHRH4MAPK8CCR4
SCHEMBL4110035 0.89 CXCR4 (0.42) CXCR4FAAHHRH4MAPK8CCR4
SCHEMBL4110231 0.89 CXCR4 (0.42) CXCR4FAAHHRH4MAPK8CCR4
SCHEMBL230553 0.87 CXCR4 (0.51) CXCR4HRH4MAPK8HRH3
SCHEMBL229157 0.87 CXCR4 (0.51) CXCR4HRH4MAPK8HRH3
SCHEMBL4109605 0.85 CXCR4 (0.41) ALDH1A1KDM4ECXCR4HRH4MRGPRX1
SCHEMBL4110591 0.85 CXCR4 (0.50) CXCR4HRH4MAPK8HRH3
SCHEMBL4105351 0.84 CXCR4 (0.47) CXCR4HRH4MAPK8CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680092-B2 Nitrogenous heterocyclic compound and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 — — US disclosed
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-09-17 — — US disclosed
EP-1852432-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF CXCR4, CXCR1, CXCL12 ALDH1A1 403/4885KDM4E 4423/4885HSD17B10 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback